- Home
- CMRX vs ITIC Comparison
CMRX vs ITIC Comparison
Compare CMRX & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMRX
- ITIC
- Stock Information
- Founded
- CMRX 2000
- ITIC 1972
- Country
- CMRX United States
- ITIC United States
- Employees
- CMRX N/A
- ITIC N/A
- Industry
- CMRX Biotechnology: Pharmaceutical Preparations
- ITIC Specialty Insurers
- Sector
- CMRX Health Care
- ITIC Finance
- Exchange
- CMRX Nasdaq
- ITIC Nasdaq
- Market Cap
- CMRX 394.1M
- ITIC 423.0M
- IPO Year
- CMRX 2013
- ITIC N/A
- Fundamental
- Price
- CMRX $5.15
- ITIC $224.28
- Analyst Decision
- CMRX Strong Buy
- ITIC
- Analyst Count
- CMRX 2
- ITIC 0
- Target Price
- CMRX $8.50
- ITIC N/A
- AVG Volume (30 Days)
- CMRX 1.7M
- ITIC 10.3K
- Earning Date
- CMRX 03-07-2025
- ITIC 02-13-2025
- Dividend Yield
- CMRX N/A
- ITIC 7.06%
- EPS Growth
- CMRX N/A
- ITIC 43.49
- EPS
- CMRX N/A
- ITIC 16.43
- Revenue
- CMRX $159,000.00
- ITIC $258,298,000.00
- Revenue This Year
- CMRX N/A
- ITIC N/A
- Revenue Next Year
- CMRX $1,690.28
- ITIC N/A
- P/E Ratio
- CMRX N/A
- ITIC $13.65
- Revenue Growth
- CMRX N/A
- ITIC 15.03
- 52 Week Low
- CMRX $0.75
- ITIC $146.41
- 52 Week High
- CMRX $5.53
- ITIC $290.40
- Technical
- Relative Strength Index (RSI)
- CMRX 76.25
- ITIC 44.36
- Support Level
- CMRX $3.94
- ITIC $220.01
- Resistance Level
- CMRX $5.53
- ITIC $233.74
- Average True Range (ATR)
- CMRX 0.30
- ITIC 5.38
- MACD
- CMRX 0.07
- ITIC 0.93
- Stochastic Oscillator
- CMRX 78.29
- ITIC 37.02
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
About ITIC Investors Title Company
Investors Title Co operates primarily in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment primarily issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.